Clinical Trials · NCT04597411
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
- Phase
- Phase 1
- Recruitment status
- Active Not Recruiting
- Sponsor
- Endocyte
- Enrollment
- 101
- Start date
- Apr 2021
- Locations
- 2 sites, Australia, South Africa
- Primary endpoint
- Recommended Phase 2 Dose (RP2D)